Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study
Executive Summary
A version of the diabetes drug intended to reduce PPAR gamma activation shows hoped for benefits and safety in a Phase II study. Poxel will now choose to advance one of two mid-stage NASH candidates.
You may also be interested in...
Stock Watch: Poxel Passes Go…But To Where?
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
Poxel/Sumitomo's Novel Diabetes Therapy Imeglimin Nears Japan Market
Poxel’s potential first-in-class diabetes therapy, imeglimin, could be approved in Japan this year, and a new partner is being sought for the EU and US – events that would transform the outlook for the decade-old Merck Serono spin-out.
Poxel’s Phase II Data Add AMP Kinase Activation To NASH Possibilities
Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.